NASDAQ · PHARMACEUTICAL PREPARATIONS
Bolt Biotherapeutics, Inc. BOLT
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.7M
▲ 0.1% vs FY2024
EPS · FY25
$-17.85
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-79.7%
Net margin · FY25
-433.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.7M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 434 cents on every revenue dollar this year.
Per share
USD -17.85
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-79.7%
Return on equity, FY2025
ROE
Operating margin-469.3%
Net margin-433.7%
Return on assets-42.7%
Each USD of equity lost 80 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+101.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+10.3%
+101.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 56.7M
total assets, end of FY2025
Total assetsUSD 56.7M
EquityUSD 26.5M
CashUSD 11.7M
Current ratio3.59×
Equity funds 47% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−17.85
−33.06
−1.83
−2.36
−2.97
−28.89
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−79.7
−74.3
−48.7
−41.8
−135.8
·
Shares out B
0.00
0.00
0.04
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
17 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed